Ocugen has announced that the second phase of the OCU410 ArMaDa clinical trial will continue followi...

Aviceda Therapeutics has successfully closed a $207.5 million Series C financing round to advance it...

The U.S. Food and Drug Administration (FDA) has accepted a revised supplemental New Drug Application...

Bausch + Lomb has announced the acquisition of Whitecap Biosciences, LLC, a biotechnology company de...

PulseSight Therapeutics SAS has submitted a clinical trial authorization (CTA) to the Agence Nationa...

Inflammasome Therapeutics has announced encouraging 3-month topline results from a clinical trial ev...

Iveric Bio has received permanent J-code from CMS for its GA treatment, Izervay (avacincaptad pegol ...

Apellis Pharmaceuticals has announced that the Therapeutic Goods Administration (TGA) of Australia h...

SeaBeLife has announced promising in vivo preclinical results for its investigational drug SBL03, an...

A large retrospective study analyzing the visual outcomes and risk of neovascular age-related macula...